Effect of chronic administration of magnesium sulfate on 1-methyl-4- phenyl-l,2,3,6-tetrahydropyridine-induced neurotoxicity in mice

Pharmacology and Toxicology

Volumn 82, Issue 5, 1998, Pages 218-222

  Tariq, Mohammad ^a   Ahmed Khan, Haseeb ^a   Al Moutaery, Khalaf ^a   Al Deeb, Saleh M ^a  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; MAGNESIUM SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLIMBING; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MORTALITY; MOUSE; NEUROTOXICITY; NOCICEPTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL;

ANIMALIA;

EID: 7144256251     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1998.tb01428.x     Document Type: Article

References (32)

1. Altura, B. M.: Calcium antagonist properties of magnesium: Implications for antimigraine actions. Magnesium 1985, 4, 169-175.
2. Arai, N., K. Misugi, Y. Goshima & Y. Misu: Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 Black mouse model for Parkinsonism. Brain Res. 1990, 515, 57-63.
3. Boadle-Biber, M. C.: Activation of tryptophan hydroxylase from central serotonergic neurons by calcium and depolarization. Biochem. Pharmacol. 1978, 27, 1069-1079.
4. Chan, P., L. E. DeLanney, I. Irwin, J. W. Langston & D. De Monte: Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 1991, 57(1), 348-351.
5. Chiueh, C. C., H. Miyake & M. T. Peng: Role of dopamine autooxidation, hydroxyl radical generation and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv. Neurol. 1993, 60, 251-258.
6. Chiueh, C. C., R. M. Wu, K. P. Mohanakumar, L. M. Sternberger, G. Krishna, T. Obata & D. L. Murphy: In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann. N. Y. Acad. Sci. 1994, 738, 25-36.
7. Essman, W. B.: Cerebral hypomagnesemia and seizure susceptibility interdependence of 5-hydroxytryptamine metabolism. In: Magnesium in health and disease. Eds.: M. Casstein & M. S. Seehing. Spectrum Publications, New York, 1980, pp. 785-790.
8. Flint, R. S., J. M. Murphy & W. J. Me Bride: Release of endogenous dopamine, 3,4-dihydroxy-phenylacetic acid, and amino acid transmitters from rat striatal slices. Neurochem. Res. 1985, 10, 515-527.
9. Fuller, R. W., S. K Hemrick-Luecke & K. W. Perry: Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J. Pharmacol. Exp. Therap. 1988, 247(2), 531-535.
10. + after administration of lethal and sublethal doses of MPTP to mice. Toxicol. Lett. 1990, 54(2-3), 253-262.
11. Gajdusek, D. C. & A. M. Salazar: Amyotrophic lateral sclerosis and parkinsonism syndromes in high incidence among the Auyu and Jakai people of West New Guinea. Neurology 1982, 32, 107-126.
12. Garcia-Ruiz, P. J., D. E. Garcia, J. Yebenes, F. J. Jimenez-Jimenez, A. Vasquez, D. Garcia-Urra & B. Morales: Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin. Neuropharmacol. 1992, 15, 19-26.
13. Garruto, R. M., S. K. Shankar, R. Yanagihara, A. M. Salazar, H. L. Amyx & D. C. Gajdusek: Low-calcium, high-aluminum diet-induced motor neuron pathology in cynomolgus monkeys. Acta neuropathol. 1989, 78, 210-219.
14. Irwin, I., E. Y. Wu, L. E. De Lanney, A. Trevor & J. W. Langston: The effect of diethyl-dithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity. Eur. J. Pharmacol. 1987, 141(2), 209-217.
15. Iseri, L. T. & J. H. French: Magnesium: nature's physiologic calcium blocker. Amer. Heart J. 1984, 108, 188-193.
16. Izenwasser, S. E., K. Garcia-Valdez & K. M. Kantak: Stimulant-like effects of magnesium on aggression in mice. Pharmacol. Biochem. Behav. 1986, 25, 1195-1199.
17. Kantak, K. M.: Magnesium deficiency alters aggressive behavior and catecholaminc function. Behav. Neurosci. 1988, 102, 29-33.
18. Kantak, K. M. & L. K. Alderstein: Enhancement of apomorphine and 1-amphetamine induced behaviors by magnesium. Pharmacol. Biochem. Behav. 1990, 36, 29-33.
19. +): Identification of a metabolite of MPTP, a toxin to the substantia nigra. Neurosci. Lett. 1984, 48, 87-92.
20. Miller, D. B., J. F. Reinhard Jr., A. J. Daniels & J. P. O'Callaghan: Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-letrahydropyridine and in vitro 1-methyl-4-phenylpyridinium. J. Neurochem. 1991, 57, 541-549.
21. Nowak, L., P. Bregestovski, P. Archer, A. Herbelt & A. Prochiantz: Magnesium gates glutamate-activated channels in mouse central neurons. Nature 1984, 307, 462-465.
22. Ogawa, N., K. Mizukawa, Y. Hirose, S. Kajita, S. Ohara & Y. Watanabe: MPTP-induced Parkinsonism model in mice: biochemistry, pharmacology and behavior. Eur. Neurol. 1987, 26, 16-23.
23. Patrick, O. E., M. Hirohisa, K. Masahiro, & M. Koreaki: Central nervous system bioaminergic responses to mechanic trauma. Surg. Neurol. 1991, 35, 273-279.
24. Raese, J. D., A. M. Edelman, G. Malck, E. A. Bruchwich, W. Lovenberg & J. D. Barchas: Brain striatal tyrosine hydroxylase: Activation of the enzyme by cyclic AMP-independent phosphorylation. Commun. Psychopharmacol. 1979, 3, 295-301.
25. Reinhart, R. A.: Clinical correlates of the molecular and cellular actions of magnesium on the cardiovascular system. Amer. Heart J. 1991, 121, LS13-1521.
26. Riederer, P., E. Sofie, W. D. Rausch, et al.: Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J. Neurochem. 1989, 52, 515-520.
27. Singer, T. P., N. Castagnoli Jr., R. R. Ramsay & A. J. Trevor: Biochemical events in the development of parkinsonism induced by 1-melhyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Neurochem. 1987, 49, 1-8.
28. Steffen, V., M. Santiago, C. P. de la Cruz, E. Ravilla, A. Machado & J. Cano: Effect of intraventricular injection of 1-methyl-4-phenylpyridinium: protection by acetyl-L-carnitine. Hum. Exp. Toxicol. 1995, 14(11), 865-871.
29. Tanner, C. M., B. Chen, W. Z. Wang, et al.: Environmental factors in the etiology of Parkinson's disease. Can. J. Neurol. Sci. 1987, 14, 419-423.
30. Taylor, J. S., D. B. Vigneson, J. Murphy-Boesch, S. J. Nelson, H. B. Kessler, L. Coia, W. Curran & T. R. Brown: Free magnesium levels in normal human brain tumors: 31P chemical shift imaging measurements at 1.5T. Proc. Natl. Acad. Sci. USA 1991, 88(15), 6810-6814.
31. Vaglini, F., F. Fascetti, F. Fornai, R. Maggio & G. U. Corsini: (+) MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice. Brain Res. 1994, 668, 194-203.
32. Yusui, M., K. Ota & R. M. Garruto: Effects of calcium-deficient diets on manganese deposition in the central nervous system and bones of rats. Neurotoxicology 1995, 16, 511-517.